Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.

[1]  M. Nørgaard,et al.  Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. , 2014, European urology.

[2]  J. Carles,et al.  Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study. , 2014, Clinical advances in hematology & oncology : H&O.

[3]  J. Persson,et al.  Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer , 2013, Drug design, development and therapy.

[4]  J. Palvimo,et al.  FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™) , 2013, Molecular and Cellular Endocrinology.

[5]  Thomas Wiegel,et al.  Guidelines on Prostate Cancer , 2013 .

[6]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[7]  S. Basaria,et al.  Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications. , 2012, Asian journal of andrology.

[8]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[9]  M. Wirth,et al.  Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years , 2010, BJU international.

[10]  G. Andriole.  Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks , 2009 .

[11]  N. Keating,et al.  Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy , 2009, Journal of General Internal Medicine.

[12]  Xianglin L. Du,et al.  Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer , 2009, Cancer.

[13]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[14]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[15]  P. Carroll,et al.  Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. , 2009, European urology.

[16]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[17]  S. Fosså,et al.  An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. , 2008, European journal of cancer.

[18]  I. Derweesh,et al.  Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer , 2008, BJU international.

[19]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Tammela,et al.  Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration , 2006, BJU international.

[21]  E. Crawford,et al.  A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. , 2003, The Journal of urology.

[22]  J. Nelson,et al.  Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[23]  A. Zietman,et al.  Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  O. Sartor,et al.  An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. , 2003, Urology.

[25]  Anthony L Zietman,et al.  Changes in body composition during androgen deprivation therapy for prostate cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[26]  M. Parmar,et al.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[27]  T. Tammela,et al.  Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. , 2000, The Journal of urology.

[28]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.

[29]  G G Klee,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable Estroge , 2022 .

[30]  T. Tammela,et al.  A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer , 1998, European Urology.

[31]  P. Schellhammer,et al.  Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. , 1996, Urology.

[32]  P. Cangh,et al.  Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer , 1994, Clinical endocrinology.

[33]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.